Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. 2005 Sep; 60(9): 773–780.
Published online 2005 Jun 30. doi:  10.1136/thx.2005.042564
PMCID: PMC1747526

Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis


Background: Cystic fibrosis (CF) airways are characterised by chronic inflammation, increased interleukin (IL)-8 secretion, and neutrophil activation which are considered the principal factors of morbidity and mortality in CF patients. Optimising management of this chronic inflammatory response is therefore a key issue of basic and clinical CF research. Several reports have addressed ways to manage CF airways inflammation, and an attractive therapeutic strategy may be the inhibition of the p38-mitogen activated protein kinase (p38-MAP-k) pathway.

Methods: A new ex vivo model was used to study the mucosal inflammatory response to environmental airways stimuli. Nasal biopsy tissues from CF patients and controls were cultured ex vivo for 20 minutes, 4 hours, and 24 hours in the presence of lipopolysaccharide (LPS) from Pseudomonas aeruginosa (PA) with and without the p38-MAP-k inhibitor SB203580. Quantitative mRNA assessment, immunohistochemistry, and Western blots were used to detect the expression and modulation of inflammatory markers.

Results: PA-LPS challenge induced a time dependent mucosal inflammation indicated by rapid epithelial activation, IL-8 release, COX-2 upregulation, and neutrophil migration to the upper mucosal layers. Some of these LPS induced changes (IL-8 release and neutrophil migration) were specific to CF tissues. SB203580 significantly controlled all LPS induced mucosal changes in CF tissues.

Conclusion: These findings provide a rationale and proof of principle for the potential use of p38-MAP-k inhibitors to control inflammation in patients with CF.

Full Text

The Full Text of this article is available as a PDF (396K).

Supplementary Material

[Web-only report]

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Ratjen Felix, Döring Gerd. Cystic fibrosis. Lancet. 2003 Feb 22;361(9358):681–689. [PubMed]
  • Berger Melvin. Lung inflammation early in cystic fibrosis: bugs are indicted, but the defense is guilty. Am J Respir Crit Care Med. 2002 Apr 1;165(7):857–858. [PubMed]
  • Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, Jacquot J. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J Immunol. 2000 Mar 15;164(6):3377–3384. [PubMed]
  • Karp Christopher L, Flick Leah M, Park Kiwon W, Softic Samir, Greer Todd M, Keledjian Raquel, Yang Rong, Uddin Jasim, Guggino William B, Atabani Sowsan F, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol. 2004 Apr;5(4):388–392. [PubMed]
  • Becker Marie N, Sauer Mariam S, Muhlebach Marianne S, Hirsh Andrew J, Wu Qi, Verghese Margrith W, Randell Scott H. Cytokine secretion by cystic fibrosis airway epithelial cells. Am J Respir Crit Care Med. 2004 Mar 1;169(5):645–653. [PubMed]
  • Wagner John A, Nepomuceno Ilynn B, Messner Anna H, Moran Mary Lynn, Batson Eric P, Dimiceli Sue, Brown Byron W, Desch Julie K, Norbash Alexander M, Conrad Carol K, et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther. 2002 Jul 20;13(11):1349–1359. [PubMed]
  • Konstan Michael W, Davis Pamela B. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev. 2002 Dec 5;54(11):1409–1423. [PubMed]
  • Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002 Sep 28;360(9338):978–984. [PubMed]
  • Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, Londei M. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology. 2000 Oct;119(4):996–1006. [PubMed]
  • Maiuri Luigi, Ciacci Carolina, Ricciardelli Ida, Vacca Loredana, Raia Valeria, Auricchio Salvatore, Picard Jean, Osman Mohamed, Quaratino Sonia, Londei Marco. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet. 2003 Jul 5;362(9377):30–37. [PubMed]
  • Kingdom TT, Lee KC, FitzSimmons SC, Cropp GJ. Clinical characteristics and genotype analysis of patients with cystic fibrosis and nasal polyposis requiring surgery. Arch Otolaryngol Head Neck Surg. 1996 Nov;122(11):1209–1213. [PubMed]
  • Loitsch SM, von Mallinckrodt C, Kippenberger S, Steinhilber D, Wagner TO, Bargon J. Reactive oxygen intermediates are involved in IL-8 production induced by hyperosmotic stress in human bronchial epithelial cells. Biochem Biophys Res Commun. 2000 Sep 24;276(2):571–578. [PubMed]
  • Reddi Krisanavane, Phagoo Stephen B, Anderson Kathryn D, Warburton David. Burkholderia cepacia-induced IL-8 gene expression in an alveolar epithelial cell line: signaling through CD14 and mitogen-activated protein kinase. Pediatr Res. 2003 Sep;54(3):297–305. [PubMed]
  • Ratner AJ, Bryan R, Weber A, Nguyen S, Barnes D, Pitt A, Gelber S, Cheung A, Prince A. Cystic fibrosis pathogens activate Ca2+-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. J Biol Chem. 2001 Jun 1;276(22):19267–19275. [PubMed]
  • Nick Jerry A, Young Scott K, Arndt Patrick G, Lieber Jonathan G, Suratt Benjamin T, Poch Katie R, Avdi Natalie J, Malcolm Ken C, Taube Christian, Henson Peter M, et al. Selective suppression of neutrophil accumulation in ongoing pulmonary inflammation by systemic inhibition of p38 mitogen-activated protein kinase. J Immunol. 2002 Nov 1;169(9):5260–5269. [PubMed]
  • Raia V, Maiuri L, de Ritis G, de Vizia B, Vacca L, Conte R, Auricchio S, Londei M. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatr Res. 2000 Mar;47(3):344–350. [PubMed]
  • Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett. 1995 May 8;364(2):229–233. [PubMed]
  • Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402–408. [PubMed]
  • Castaldo G, Polizzi A, Tomaiuolo R, Cazeneuve C, Girodon E, Santostasi T, Salvatore D, Raia V, Rigillo N, Goossens M, et al. Comprehensive cystic fibrosis mutation epidemiology and haplotype characterization in a southern Italian population. Ann Hum Genet. 2005 Jan;69(Pt 1):15–24. [PubMed]
  • Engel K, Schultz H, Martin F, Kotlyarov A, Plath K, Hahn M, Heinemann U, Gaestel M. Constitutive activation of mitogen-activated protein kinase-activated protein kinase 2 by mutation of phosphorylation sites and an A-helix motif. J Biol Chem. 1995 Nov 10;270(45):27213–27221. [PubMed]
  • Zeilhofer HU, Schorr W. Role of interleukin-8 in neutrophil signaling. Curr Opin Hematol. 2000 May;7(3):178–182. [PubMed]
  • Brennan Amanda L, Geddes Duncan M. Cystic fibrosis. Curr Opin Infect Dis. 2002 Apr;15(2):175–182. [PubMed]
  • Schmeck Bernd, Zahlten Janine, Moog Kerstin, van Laak Vincent, Huber Sylvia, Hocke Andreas C, Opitz Bastian, Hoffmann Elke, Kracht Michael, Zerrahn Jens, et al. Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor. J Biol Chem. 2004 Dec 17;279(51):53241–53247. [PubMed]
  • Jijon H, Allard B, Jobin C. NF-kappaB inducing kinase activates NF-kappaB transcriptional activity independently of IkappaB kinase gamma through a p38 MAPK-dependent RelA phosphorylation pathway. Cell Signal. 2004 Sep;16(9):1023–1032. [PubMed]
  • Hollenbach Eike, Vieth Michael, Roessner Albert, Neumann Manfred, Malfertheiner Peter, Naumann Michael. Inhibition of RICK/nuclear factor-kappaB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J Biol Chem. 2005 Apr 15;280(15):14981–14988. [PubMed]
  • Alvarado-Kristensson Maria, Melander Fredrik, Leandersson Karin, Rönnstrand Lars, Wernstedt Christer, Andersson Tommy. p38-MAPK signals survival by phosphorylation of caspase-8 and caspase-3 in human neutrophils. J Exp Med. 2004 Feb 16;199(4):449–458. [PMC free article] [PubMed]
  • Zaman Munir M, Gelrud Andres, Junaidi Omer, Regan Meredith M, Warny Michel, Shea Julie C, Kelly Ciaran, O'Sullivan Brian P, Freedman Steven D. Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol. 2004 Sep;11(5):819–824. [PMC free article] [PubMed]
  • Cara DC, Kaur J, Forster M, McCafferty DM, Kubes P. Role of p38 mitogen-activated protein kinase in chemokine-induced emigration and chemotaxis in vivo. J Immunol. 2001 Dec 1;167(11):6552–6558. [PubMed]
  • Nick JA, Young SK, Brown KK, Avdi NJ, Arndt PG, Suratt BT, Janes MS, Henson PM, Worthen GS. Role of p38 mitogen-activated protein kinase in a murine model of pulmonary inflammation. J Immunol. 2000 Feb 15;164(4):2151–2159. [PubMed]
  • Kim Jin Young, Kang Young-Sun, Lee Joong-Won, Kim Hyoung June, Ahn Young Ha, Park Heonyong, Ko Young-Gyu, Kim Sunghoon. p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex: implications for its physiological significance. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7912–7916. [PMC free article] [PubMed]
  • Kumar Sanjay, Boehm Jeffrey, Lee John C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov. 2003 Sep;2(9):717–726. [PubMed]
  • Schultz Richard M. Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog Drug Res. 2003;60:59–92. [PubMed]
  • Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology. 2000 May;47(2-3):185–201. [PubMed]
  • Stelmach John E, Liu Luping, Patel Sangita B, Pivnichny James V, Scapin Giovanna, Singh Suresh, Hop Cornelis E C A, Wang Zhen, Strauss John R, Cameron Patricia M, et al. Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase. Bioorg Med Chem Lett. 2003 Jan 20;13(2):277–280. [PubMed]
  • Newton Robert, Holden Neil. Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma? BioDrugs. 2003;17(2):113–129. [PubMed]

Articles from Thorax are provided here courtesy of BMJ Group


Save items

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...